BDTX
Black Diamond Therapeutics Inc
NASDAQ: BDTX · HEALTHCARE · BIOTECHNOLOGY
$2.65
+3.11% today
Updated 2026-04-30
Market cap
$170.15M
P/E ratio
7.62
P/S ratio
2.43x
EPS (TTM)
$0.39
Dividend yield
—
52W range
$1 – $5
Volume
0.7M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
4.3
Growth
C7.0
Quality
B+9.0
Profitability
A+8.3
Valuation
A4/9
Piotroski F-Score
Moderate
-2.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$9.71
+266.42%
12-Month target
$2.19
-17.36%
Intrinsic (DCF)
$5.24
Margin of safety
+57.63%
2 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 32.00% — above average
+ ROE 22.90% — strong efficiency
+ 57.63% below intrinsic value
+ Debt/equity 0.13x — low leverage
Risks
- Altman Z -2.40 — distress zone
- Negative free cash flow $-6.79M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $70.00M | $70.00M |
| Net income | $-91.17M | $-82.44M | $-69.68M | $22.37M | $-15.12M |
| EPS | — | — | — | — | $0.39 |
| Free cash flow | $-85.27M | $-66.75M | $-62.30M | $29.61M | $-6.79M |
| Profit margin | — | — | — | 31.95% | 32.00% |
Peer comparison
Smart narrative
Black Diamond Therapeutics Inc trades at $2.65. representing a P/E of 7.62x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.40, it sits in the distress. TTM revenue stands at $70.00M. with profit margins at 32.00%. Our DCF model estimates intrinsic value at $5.24.
Frequently asked questions
What is Black Diamond Therapeutics Inc's stock price?
Black Diamond Therapeutics Inc (BDTX) trades at $2.65.
Is Black Diamond Therapeutics Inc overvalued?
Smart Value Score 58/100 (Grade C+, Hold). DCF value $5.24.
What is the price target of Black Diamond Therapeutics Inc (BDTX)?
The analyst target price is $9.71, representing +266.4% upside from the current price of $2.65.
What is the intrinsic value of Black Diamond Therapeutics Inc (BDTX)?
Based on our DCF model, intrinsic value is $5.24, a +57.6% margin of safety versus $2.65.
What is Black Diamond Therapeutics Inc's revenue?
TTM revenue is $70.00M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.40 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.43x
ROE22.90%
Beta3.39
50D MA$2.42
200D MA$2.95
Shares out0.06B
Float0.05B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—